×
About 3,973 results

ALLMedicine™ Chronic Myelogenous Leukemia Center

Research & Reviews  1,128 results

c-Abl controls BCR signaling and B cell differentiation by promoting B cell metabolism.
https://doi.org/10.1111/imm.13525
Immunology Luo L, Jiang P et. al.

Jun 27th, 2022 - As a non-receptor tyrosine kinase, c-Abl was first studied in chronic myelogenous leukemia, and its role in lymphocytes has been well characterized. c-Abl is involved in B cell development and CD19 associated B cell antigen receptor (BCR) signalin...

Biology Studies of Hematologic Cancers
https://clinicaltrials.gov/ct2/show/NCT00923442

Jun 24th, 2022 - Background: Laboratory-based investigations have contributed to an improved understanding of pathophysiology and to the development of new therapies for hematologic malignancies. The aim of this protocol is to facilitate biologic study of leukemia...

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

Jun 24th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

Jun 24th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Coiled-coil heterodimer-based recruitment of an exonuclease to CRISPR/Cas for enhanced ...
https://doi.org/10.1038/s41467-022-31386-1 10.1126/science.1225829 10.1016/j.cell.2014.05.010 10.1126/science.1232033 10.1038/s41580-019-0131-5 10.1016/j.cell.2014.02.001 10.1038/nature17664 10.1038/ncb3452 10.1146/annurev-biochem-060815-014607 10.1038/nbt.3026 10.1038/nbt.2909 10.1016/j.cell.2013.08.021 10.1038/nature16526 10.1038/nbt.4066 10.1038/s41467-019-13226-x 10.1038/nature24049 10.1016/j.cell.2015.09.038 10.1038/s41586-019-1711-4 10.1038/nature17946 10.3389/fgene.2019.00365 10.1038/nbt.3149 10.1038/nchembio.1793 10.1038/nrm804 10.1128/ecosalplus.4.4.7 10.1371/journal.pone.0053217 10.1038/nmeth.2177 10.1038/srep01253 10.1002/dvg.23044 10.1007/s11427-020-1671-6 10.1016/S0962-8924(00)01898-5 10.1038/nbt.3994 10.1038/nchembio.1248 10.1126/science.1257452 10.1038/s41589-018-0181-6 10.1038/s41589-019-0443-y 10.1038/nm.3793 10.1021/acssynbio.8b00192 10.1038/nature13011 10.1021/jacs.7b13047 10.1038/nature13589 10.1016/j.cell.2014.09.014 10.1021/jacs.7b01690 10.1038/s41598-021-88315-3 10.1038/s41598-016-0028-x 10.1038/nmeth.4278 10.1038/s41596-018-0055-0 10.1016/j.ymthe.2021.09.003 10.1038/s41587-020-0555-7 10.1038/mt.2016.10 10.18632/oncotarget.20874 10.18632/oncotarget.15215 10.1186/s12943-018-0801-5 10.1038/s41598-016-0001-8 10.1126/science.aba7365 10.1038/nature13589 10.1038/srep10777 10.1073/pnas.1501698112 10.1038/s41467-020-20314-w 10.1038/s41551-019-0501-5 10.1158/1078-0432.CCR-16-1300 10.1038/s41591-020-0840-5 10.1093/nar/gku936 10.1038/nbt.3583 10.1038/s41587-019-0032-3
Nature Communications; Lainšček D, Forstnerič V et. al.

Jun 24th, 2022 - The CRISPR/Cas system has emerged as a powerful and versatile genome engineering tool, revolutionizing biological and biomedical sciences, where an improvement of efficiency could have a strong impact. Here we present a strategy to enhance gene ed...

see more →

Guidelines  5 results

JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myel...
https://doi.org/10.1007/s12185-017-2330-1
International Journal of Hematology; Usui N

Sep 25th, 2017 - JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).|2017|Usui N,|administration & dosage,administration & dosage,administration & dosage,administration &...

Chronic Myelogenous Leukemia, Version 1.2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Radich JP et. al.

Nov 15th, 2013 - The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring m...

Chronic myelogenous leukemia.
https://doi.org/10.6004/jnccn.2012.0009
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Abboud CN et. al.

Jan 10th, 2012 - Chronic myelogenous leukemia.|2012|O'Brien S,Abboud CN,Akhtari M,Altman J,Berman E,|therapeutic use,diagnosis,drug therapy,therapy,therapeutic use,

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
https://doi.org/10.6004/jnccn.2009.0065
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Berman E et. al.

Nov 3rd, 2009 - NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.|2009|O'Brien S,Berman E,Borghaei H,Deangelo DJ,Devetten MP,|therapeutic use,diagnosis,drug therapy,surgery,

Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatmen...
https://doi.org/10.1093/annonc/mdn091
Annals of Oncology : Official Journal of the European Soc... Hochhaus A, Dreyling M et. al.

May 9th, 2008 - Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up.|2008|Hochhaus A,Dreyling M, ,|diagnosis,epidemiology,therapy,

see more →

Drugs  23 results see all →

Clinicaltrials.gov  278 results

Biology Studies of Hematologic Cancers
https://clinicaltrials.gov/ct2/show/NCT00923442

Jun 24th, 2022 - Background: Laboratory-based investigations have contributed to an improved understanding of pathophysiology and to the development of new therapies for hematologic malignancies. The aim of this protocol is to facilitate biologic study of leukemia...

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

Jun 24th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

Jun 24th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Tra...
https://clinicaltrials.gov/ct2/show/NCT01640301

Jun 23rd, 2022 - PRIMARY OBJECTIVES: I. Determine the safety and potential toxicities associated with treating patients with high risk or relapsed AML, MDS, and CML after allogeneic hematopoietic cell transplantation (HCT) by adoptive transfer of virus-specific cl...

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04795427

Jun 21st, 2022 - The purpose of this Chinese bridging study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of asciminib versus best available therapy (BAT) in Chinese patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP)...

see more →

News  151 results

Dr. Ron Bose on HER2 Gene Mutations in Breast Cancer
https://www.onclive.com/view/dr-ron-bose-on-her2-gene-mutations-in-breast-cancer

Oct 6th, 2021 - Ron Bose, MD, PhD, assistant professor in the Division of Oncology at Washington University School of Medicine and the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer. Overall, Bose ...

Life Expectancy Still Lower for Blood or Marrow Transplant Recipients
https://www.medpagetoday.com/hematologyoncology/hematology/94425

Sep 9th, 2021 - While late mortality among recipients of allogeneic blood or marrow transplantation (BMT) has decreased over the past 4 decades, life expectancy among these patients remains shorter versus the U.S. population at large, a retrospective cohort study...

Clinical Edge Journal Scan Commentary: CML September 2021
https://www.mdedge.com/hematology-oncology/article/245751/cml/clinical-edge-journal-scan-commentary-cml-september-2021
Javier Pinilla-Ibarz MD, PhD

Sep 7th, 2021 - Javier Pinilla-Ibarz MD, PhD Chronic myelogenous leukemia ( CML) is a relatively rare leukemia in pediatric population and although allogenic bone marrow transplant used to be commonly used even in the earlier times of TKIs therapy, the superior s.

No Age Limit for Bone Marrow Transplantation
https://www.onclive.com/view/no-age-limit-for-bone-marrow-transplantation

Aug 17th, 2021 - Rainer Storb, MD Member, Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for...

Dr. Zelenetz on Treating Hematologic Malignancies
https://www.onclive.com/view/dr-zelenetz-on-treating-hematologic-malignancies

Aug 17th, 2021 - Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine; Chief, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancie...

see more →

Patient Education  4 results see all →